Plain-language trial education for patients and families, and clinical-trials commentary for research professionals — written by ClinicalMatch founder Dr. Viktoriia Golikova, MD.
Showing 7 posts.
Two September accelerated approvals illustrate a recurring recruitment tension: once a drug is available, the trials meant to confirm its benefit have to compete with the market.
Read more →Joining a trial is a decision, not a signature. Here are the questions worth asking the study team and your own doctor before you say yes.
Read more →Three October oncology approvals share a pattern: eligibility defined by biomarker, treatment timing, or disease subtype. What that means for protocol design and site feasibility.
Read more →A field-by-field guide to the parts of a trial listing that matter most — status, phase, eligibility, and contacts — so you can tell quickly whether a study might fit.
Read more →A short placeholder post on how the move toward decentralized and hybrid trial design is changing feasibility and site-activation planning.
Read more →A plain-language breakdown of what a trial sponsor typically covers, what your insurance is typically expected to cover, and the questions worth asking before you enroll.
Read more →Phase 1, 2, 3, 4 — what each one is actually testing, and why the difference matters when you're looking at trials for yourself or someone you love.
Read more →